Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.42 |
| ▸ | ABL1 | P00519 | 4/20 | 0.38 |
| ▸ | BCR | P11274 | 3/20 | 0.38 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.36 |
| ▸ | CDK9 | P50750 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.36 |
| ▸ | ABL2 | P42684 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17129834 | 0.87 | SYK (0.48) | SYKABL1BCRGRM4GSK3A | |
| SCHEMBL17113597 | 0.86 | SYK (0.47) | SYKABL1GSK3AMAPK14HTR2A | |
| SCHEMBL17113474 | 0.81 | SYK (0.63) | SYKABL1BCRCCNT1CDK9 | |
| SCHEMBL17113285 | 0.71 | SYK (0.69) | SYKABL1BCRCCNT1CDK9 | |
| SCHEMBL17113604 | 0.70 | SYK (0.55) | SYKABL1CCNT1CDK9 | |
| SCHEMBL17113491 | 0.70 | SYK (0.68) | SYKABL1BCRCCNT1CDK9 | |
| SCHEMBL17113289 | 0.70 | SYK (0.67) | SYKABL1BCRCCNT1CDK9 | |
| SCHEMBL14140330 | 0.69 | AIMP2 (0.54) | SYKABL1BCREGFRABL2 | |
| SCHEMBL17113590 | 0.68 | SYK (0.69) | SYKABL1BCRCCNT1CDK9 | |
| SCHEMBL17113328 | 0.68 | SYK (0.54) | SYKABL1BCRCCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3122744-B1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2018-11-07 | — | — | EP | claimed |
| US-10053455-B2 | Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors | AB SCIENCE (FR) | 2018-08-21 | — | — | US | claimed |
| US-20180179195-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2018-06-28 | — | — | US | claimed |
| EP-3122744-B1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2018-11-07 | — | — | EP | disclosed |
| US-10053455-B2 | Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors | AB SCIENCE (FR) | 2018-08-21 | — | — | US | disclosed |
| US-20180179195-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2018-06-28 | — | — | US | disclosed |
| US-20180179195-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2018-06-28 | — | — | US | disclosed |
| US-20180179195-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2018-06-28 | — | — | US | disclosed |
| WO-2015144614-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053455-B2 | Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors | SYK, ZAP70, LCK | SYK 1/4885ABL1 436/4885BCR 332/4885 |
| US-20180179195-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | SYK, ZAP70, LCK | SYK 1/4885ABL1 436/4885BCR 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.